{"filing":{"accession_number":"0001213900-26-084244","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"ea0300232-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026084244/ea0300232-6k_canfite.htm"},"events":[{"id":23147,"run_id":20946,"accession_number":"0001213900-26-084244","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Can-Fite announced the submission of a Phase 2 clinical study protocol for Piclidenoson in Lowe syndrome, representing the company's first clinical program for this rare genetic disease. This is a material operational and strategic milestone—the initiation of a new clinical development program in a high-need therapeutic area with no approved treatments—but does not fit the specific event categories of earnings release, M\u0026A, executive changes, or other named types. The disclosure reflects a significant expansion of the company's pipeline and development strategy.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23300,"accession_number":"0001213900-26-084244","item_number":"EX-99.1","item_title":"ea030023201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Can-Fite announced the submission of a Phase 2 clinical study protocol for Piclidenoson in Lowe syndrome, representing the company's first clinical program for this rare genetic disease. This is a material operational and strategic milestone—the initiation of a new clinical development program in a high-need therapeutic area with no approved treatments—but does not fit the specific event categories of earnings release, M\u0026A, executive changes, or other named types. The disclosure reflects a significant expansion of the company's pipeline and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:30.110920+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23300,"accession_number":"0001213900-26-084244","item_number":"EX-99.1","item_title":"ea030023201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Can-Fite announced the submission of a Phase 2 clinical study protocol for Piclidenoson in Lowe syndrome, representing the company's first clinical program for this rare genetic disease. This is a material operational and strategic milestone—the initiation of a new clinical development program in a high-need therapeutic area with no approved treatments—but does not fit the specific event categories of earnings release, M\u0026A, executive changes, or other named types. The disclosure reflects a significant expansion of the company's pipeline and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:30.110920+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-08-03"}]}